Menu
Recruiting NCT07409493

IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols

No phase Interventional Infertility (IVF Patients) Embryo Morphokinetics Progestins Primed Ovarian Stimulation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Progestin-Primed Ovarian Stimulation, Antagonist protocol for IVF.
Who it may be relevant to
Registry conditions: Infertility (IVF Patients), Embryo Morphokinetics, Progestins Primed Ovarian Stimulation. Basic parameters: 20 years — 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Vietnam
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this clinical trial is to compare two ovarian stimulation protocols used in in vitro fertilization (IVF): the fixed Progestin-Primed Ovarian Stimulation (PPOS) protocol and the GnRH Antagonist protocol. The study will evaluate IVF outcomes and embryo development patterns using time-lapse embryo monitoring technology. The main questions the study aims to answer are: * Does the fixed - PPOS protocol achieve similar numbers of mature eggs, good-quality embryos, and clinical outcomes compared to the GnRH Antagonist protocol? * Are there differences in embryo development patterns (morphokinetics) between the two protocols when monitored by time-lapse imaging? * How does embryo quality (KIDScore) compare between the two protocols? Study Design: Researchers will randomly assign 148 women undergoing IVF to two groups: * PPOS group (n=74): Will receive FSH injections (oral Duphaston 20mg daily) starting from day 2-3 of the menstrual cycle * GnRH Antagonist group (n=74): Will receive FSH injections (Orgalutran 0.25mg injections) when follicles reach ≥14mm Participants will: * Undergo controlled ovarian stimulation with their assigned protocol for approximately 10-12 days * Have regular ultrasound monitoring and blood tests to track follicle development * Undergo egg retrieval procedure when follicles are mature * Have all embryos cultured in the EmbryoScope time-lapse incubator with continuous monitoring * Have embryos frozen on Day 5/6 for future transfer Study Location: Department of Assisted Reproduction and Andrology, Hanoi Obstetrics and Gynecology Hospital Study Duration: January 2026 - June 2028

Interventions

  • Drug Progestin-Primed Ovarian Stimulation
    Ovarian stimulation using progestin-primed ovarian stimulation (PPOS) protocol. Patients receive recombinant FSH starting from day 2-3 of menstrual cycle, concomitantly with oral Dydrogesterone 20mg daily to prevent premature LH surge. All embryos are cultured using time-lapse technology and cryopreserved for subsequent frozen embryo transfer.
  • Drug Antagonist protocol for IVF
    Ovarian stimulation using GnRH antagonist protocol. Patients receive recombinant FSH starting from day 2-3 of menstrual cycle. GnRH antagonist is added when leading follicle reaches 12-14mm diameter to prevent premature LH surge. All embryos are cultured using time-lapse technology and cryopreserved for subsequent frozen embryo transfer.

Primary outcome measures

  • Blastocyst formation rate [Time frame: Day 5 to Day 6 after oocyte retrieval]
Secondary outcome measures (1)
  • Embryo morphokinetic development [Time frame: Day 2 to day 5 after oocyte retrieval]

Eligibility criteria

Inclusion criteria

  • Women aged 20-45 years
  • Indicated for in vitro fertilization (IVF) treatment
  • Planned freeze-all embryo strategy
  • Voluntary participation in research.

Exclusion criteria

  • Systemic diseases
  • Use of hormonal medications within 3 months prior to enrollment
  • Oocyte donation cycles
  • Unwilling or unable to participate in research

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Vietnam · 1 center
  • Hanoi Obstetrics and Gynecology Hospital — Hanoi

Identifiers

NCT: NCT07409493 · HMUIRB2275

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗